Here are Monday's biggest analyst calls: Nvidia, Apple, SpaceX, Dell, Deere, Broadcom, Costco, Redcat & more
Analysts made several calls on Monday. Morgan Stanley initiated Attovia Therapeutics with an overweight rating and $39 target. UBS upgraded Kaiser Aluminum to buy with an $184 target. Baird upgraded Deere to outperform. Jefferies reiterated Apple as underperform, citing potential downside risks. Bernstein reiterated SpaceX as outperform but noted uncertainty in its direct-to-device mobile business. Melius reiterated Nvidia as buy, suggesting potential upside. Goldman Sachs initiated Braveheart B
How this was made
The 30-second read
Why it matters
Collective analyst sentiment shift may provide short‑term price support for the listed tickers, but the effect is likely modest and contingent on upcoming earnings and macro data.
Market read
Analyst upgrades and new coverage collectively add modest bullish pressure to the highlighted stocks.
What to watch
Potential earnings volatility for Dell and Apple could offset upgrade optimism.
Background
The article compiles the day's most notable analyst initiations, upgrades, and price target changes across a range of U.S. listed companies.
Ticker impact
UBS upgraded Kaiser Aluminum to Buy with a $184 price target.
Modest upside if market digests upgrade.
Upgrade signals improved outlook; price target above current levels.
Baird upgraded Deere to Outperform from Neutral.
Likely short‑term rally.
Analyst cites strong demand fundamentals.
Jefferies reiterated Apple as Underperform, citing iPhone volume risk.
Potential pressure on the stock.
Analyst highlights volume and FX headwinds.
Evercore ISI initiated Lumentum as Overweight with a $1,100 target.
Possible upside if market follows target.
New coverage and high price target suggest upside.
Melius reiterated Nvidia as Buy, expecting a breakout.
Potential rally if breakout materializes.
Analyst cites strong AI tailwinds.
Evercore ISI initiated Redcat as Outperform with a $15 target.
Likely upside on contract expectations.
Unique position as publicly listed drone maker.
Needham initiated Babcock & Wilcox Enterprises as Buy with a $20 target.
Modest upside potential.
Analyst sees improved financial health.
Goldman Sachs initiated Braveheart Bio as Buy with a $48 target.
Potential upside if pipeline advances.
New coverage and high target suggest upside.
Market effects
Broad analyst upgrades lift sentiment in AI, industrial, and consumer discretionary sectors.
U.S. equities may see modest gains across upgraded names.
Limited to U.S. listed companies; no direct global macro impact.
Counterpoint
Some upgrades may be premature if macro headwinds persist, especially for consumer and industrial names.
Key entities
- Research FirmUBS
Provided upgrade for Kaiser Aluminum
- Research FirmBaird
Upgraded Deere
- Research FirmJefferies
Reiterated Apple Underperform
- Research FirmEvercore ISI
Initiated Lumentum and Redcat
- Research FirmMelius
Reiterated Nvidia Buy
